We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer's Precose, J&J's Reminyl Targeted by Paragraph IV Filings
Bayer's Precose, J&J's Reminyl Targeted by Paragraph IV Filings
May 17, 2005
Precose and Reminyl are the latest drugs to receive abbreviated new drug applications (ANDAs) with Paragraph IV certifications against them, according to the FDA’s latest list of Paragraph IV filings.